Lantheus Holdings, Inc. $LNTH Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 83.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 30,740 shares of the medical equipment provider’s stock after selling 159,268 shares during the period. Harbor Capital Advisors Inc.’s holdings in Lantheus were worth $1,577,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Reinhart Partners LLC. grew its stake in shares of Lantheus by 16.4% during the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after purchasing an additional 197,719 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Lantheus during the 3rd quarter valued at $65,654,000. Swedbank AB grew its holdings in shares of Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares in the last quarter. Boston Partners lifted its stake in shares of Lantheus by 30.5% during the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after buying an additional 134,781 shares during the period. Finally, Raymond James Financial Inc. increased its stake in Lantheus by 25.1% in the second quarter. Raymond James Financial Inc. now owns 470,678 shares of the medical equipment provider’s stock valued at $38,530,000 after purchasing an additional 94,312 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Up 0.0%

NASDAQ:LNTH opened at $66.71 on Friday. The stock has a fifty day simple moving average of $58.96 and a 200 day simple moving average of $62.35. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of 28.03 and a beta of -0.10. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm had revenue of $92.51 million during the quarter. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LNTH. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial upped their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Mizuho upped their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.